16 May 2022
\n \n \n \nThe PRINCIPLE Trial has led the way in evaluating treatments for COVID-19 in the community over the last two years.
\n \n\n \n \n22 April 2022
\n \n \n \nFinal Honours student, Harrison France, from the Nuffield Department of Primary Care Health Science and the Centre for Evidence-Based Medicine, has recently been awarded 1st place in the the IUPHAR (International Union of Basic and Clinical Pharmacology) Student Research Poster Competition 2022 by the British Pharmacological Society, for his research on preventable deaths involving medicines.
\n \n\n \n \n13 April 2022
\n \n \n \nCongratulations to the amazing team of research nurses working in the Primary Care Clinical Trials Unit who have been shortlisted as finalists in the Oxford University Hospitals NHS Foundation Trust Staff Recognition Awards 2021.
\n \n\n \n \n12 April 2022
\n \n \n \nFrom today, the antiviral treatment Paxlovid has been included in the national PANORAMIC study, the UK\u2019s fastest ever recruiting clinical trial of its kind, run by the Nuffield Department of Primary Care Health Sciences and supported by the National Institute for Health and Care research (NIHR).
\n \n\n \n \n4 April 2022
\n \n \n \n10,000 people have joined the PRINCIPLE Trial over the last two years and we want to say a big \u2018Thank You\u2019 to them all for their amazing contribution to testing treatments for COVID-19 in the community.
\n \n\n \n \n31 March 2022
\n \n \n \nThe world\u2019s largest study of community-based treatments for acute COVID-19 has reached a world-first, historic milestone: over twenty thousand participants from across the UK have now taken part in the PANORAMIC trial.
\n \n\n \n \n16 December 2021
\n \n \n \nLed by the University of Oxford, a team of UK-based researchers have today reported results of the largest ever study to compare the risks of cardiovascular events, such as myocarditis, pericarditis, and cardiac arrhythmia, between different vaccines and COVID-19 infection, and the first to investigate the association between cardiac events and the Oxford-AstraZeneca vaccine.
\n \n\n \n \n8 December 2021
\n \n \n \nResearchers from the University of Oxford have today started recruiting participants for a first-of-its-kind clinical trial to test novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 and those who are at higher risk of complications \u2013 partnering with the National Institute for Health Research (NIHR) and working with colleagues in several UK universities, and the NHS UK-wide.
\n \n\n \n \n12 November 2021
\n \n \n \nA study of cancer in children and young adults in England has found that fewer patients were diagnosed during the COVID-19 pandemic.\r\n\r\nThe research, presented at the NCRI Festival, also shows that children who were diagnosed with cancer during the first wave of the pandemic were more likely to have been admitted to intensive care prior to their diagnosis.
\n \n\n \n \n1 November 2021
\n \n \n \nAn international team of researchers, led from Centre for Evidence-based Medicine based in the Nuffield Department of Primary Care Health Sciences, University of Oxford, and funded by the World Health Organization and the National Institute for Health Research School for Primary Care Research, have today announced the findings from the most complete analysis of high-quality covid transmission studies in asymptomatic and pre-symptomatic people to date.
\n \n\n \n \n26 October 2021
\n \n \n \nResearchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.
\n \n\n \n \n25 October 2021
\n \n \n \nResearchers from across the UK, led by the University of Oxford, have today reported on the risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.
\n \n\n \n \n11 October 2021
\n \n \n \nA collaboration which used anonymised GP records to identify 1.5m people most at risk from Covid-19 and prioritise them for vaccination has won the prestigious John Perry Prize for computing innovation in primary care.
\n \n\n \n \n28 September 2021
\n \n \n \nSmoking is highly likely to worsen the severity of COVID-19 and the risk of dying with the infection, finds a large study led by researchers from the University of Oxford and published online in the respiratory journal Thorax.
\n \n\n \n \n23 September 2021
\n \n \n \nProfessor Julia Hippisley-Cox and her team have been Highly Commended in the \u2018Best use of technology in Patient Safety\u2019 category for the QCovid risk calculator at this year\u2019s Health Service Journal Patient Safety Awards.
\n \n\n \n \n20 September 2021
\n \n \n \nNew algorithm predicts those most at risk of serious Covid-19 outcomes from 14 or more days after second vaccination dose, when substantial immunity is expected to have developed Authors hope this new risk tool will allow those who perceive risk to be high to make more informed decisions regarding shielding and potentially inform policy and clinical decisions on booster vaccine doses and monoclonal antibodies
\n \n\n \n \n27 August 2021
\n \n \n \nOxford researchers have today announced the results of a blood clot study, suggesting lower risk with vaccine than infection.
\n \n\n \n \n10 August 2021
\n \n \n \nResearch into the risk of hospital admission from COVID-19 is recognised with a \"Best Research Paper Award\" from the journal Heart.
\n \n\n \n \n19 July 2021
\n \n \n \nThe Nuffield Department of Primary Care Health Sciences is delighted to announce that it has been awarded \u00a3557,674 to investigate how families are managing to cope with \u2018long covid\u2019 and to understand how best they can be supported.
\n \n\n \n \n15 July 2021
\n \n \n \nThe results, from within the OpenSAFELY platform, are based on electronic health records for more than 17 million people registered with a general practice in England linked to hospital admission and mortality data.
\n \n\n \n \n